CD4 and neoplasm: Anti-tumor activity was accompanied by a direct impact on the TME including significantly decreased FRβ-expressing TAMs, and no evidence of CD3+ T cell depletion or impact on the relative proportions of CD4+ and CD8+ T cells after drug treatment.